In the analysis of patients receiving different drugs, except for the marginally significant performance in Pertuzumab arm, CRD model shown significant association with pCR with OR of 2.88–10.93 in the other treatment arms (Fig. 5 (c)).
← all excerpts
Enhancing pathological complete response prediction in breast cancer: the role of dynamic characterization of DCE-MRI and its association with tumor heterogeneity.
1
—
—